BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21419883)

  • 1. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
    Li X; Liao J; Park SI; Koh AJ; Sadler WD; Pienta KJ; Rosol TJ; McCauley LK
    Bone; 2011 Jun; 48(6):1354-61. PubMed ID: 21419883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
    Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
    Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.
    Tannehill-Gregg SH; Levine AL; Nadella MV; Iguchi H; Rosol TJ
    Clin Exp Metastasis; 2006; 23(1):19-31. PubMed ID: 16715352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
    Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
    Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
    Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
    Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
    Pozzi S; Vallet S; Mukherjee S; Cirstea D; Vaghela N; Santo L; Rosen E; Ikeda H; Okawa Y; Kiziltepe T; Schoonmaker J; Xie W; Hideshima T; Weller E; Bouxsein ML; Munshi NC; Anderson KC; Raje N
    Clin Cancer Res; 2009 Sep; 15(18):5829-39. PubMed ID: 19737962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical, pharmacologic, and in vitro cellular effects of loading collagen membranes with zoledronic acid.
    Liao J; Meng Y; Zhai J; Wen C; Ten M; Tian A; Wang Y; Liang X
    Int J Oral Maxillofac Implants; 2013; 28(4):1027-36. PubMed ID: 23869361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
    de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
    J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches.
    Soki FN; Li X; Berry J; Koh A; Sinder BP; Qian X; Kozloff KM; Taichman RS; McCauley LK
    J Cell Biochem; 2013 Jan; 114(1):67-78. PubMed ID: 22833499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
    Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
    Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
    Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F
    BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
    Ohishi M; Chiusaroli R; Ominsky M; Asuncion F; Thomas C; Khatri R; Kostenuik P; Schipani E
    Am J Pathol; 2009 Jun; 174(6):2160-71. PubMed ID: 19389927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
    Mundy GR; Yoneda T; Hiraga T
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
    Yang C; Davis JL; Zeng R; Vora P; Su X; Collins LI; Vangveravong S; Mach RH; Piwnica-Worms D; Weilbaecher KN; Faccio R; Novack DV
    Cancer Discov; 2013 Feb; 3(2):212-23. PubMed ID: 23269702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the effects of zoledronic-acid-loaded collagen membrane on bone metabolism cells].
    Meng YH; Peng Y; Liu D; Chen Y; Wang H; Liang X
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2011 Feb; 46(2):107-11. PubMed ID: 21426781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of osteoclastogenesis after bisphosphonate therapy discontinuation: an in vitro approach.
    Bradaschia-Correa V; Ribeiro-Santos GC; de Faria LP; Rezende-Teixeira P; Arana-Chavez VE
    J Mol Histol; 2022 Aug; 53(4):669-677. PubMed ID: 35701706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
    Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
    J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
    Herrak P; Görtz B; Hayer S; Redlich K; Reiter E; Gasser J; Bergmeister H; Kollias G; Smolen JS; Schett G
    Arthritis Rheum; 2004 Jul; 50(7):2327-37. PubMed ID: 15248234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
    Hirbe AC; Roelofs AJ; Floyd DH; Deng H; Becker SN; Lanigan LG; Apicelli AJ; Xu Z; Prior JL; Eagleton MC; Piwnica-Worms D; Rogers MJ; Weilbaecher K
    Bone; 2009 May; 44(5):908-16. PubMed ID: 19442620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.